- Congratulations to the following Sloan-Kettering Institute researchers. They are the recipients of the 2012 NIH Director’s New Innovator Award Program: Ping Chi, M.D., Ph.D., An integrative approach to target lineage-specific oncogenic transcription factor; Daniel A. Heller, Ph.D.,Transient Metabolite Detection for Single-Cell Metabolomics and Diagnostics; and Alexandrosc Pertsinidis, Ph.D., Understanding Gene Transcription from First-Principles: A single-molecule study. View all recipients.
- Investigators at MSKCC, Weill Cornell Medical College, Johns Hopkins University, and The Rockefeller University have found that the nonsteroidal anti-inflammatory drug oxyphenbutazone (OPB) is an effective antimycobacterial agent that displays potent activity against nonreplicating as well as replicating populations of the bacterium.
- Sloan-Kettering & Hunter College to Build High-Tech NYC Cancer Center.
-
The National Cancer Institute awarded the Small Business Innovation Research grant to RXi for a project with Dr. David Cobrinik and others at Memorial Sloan-Kettering Cancer Center.